Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02926573 · ClinicalTrials.gov registry record · Phase 4

Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients

A Phase 4 study of Head and Neck Cancer and Postoperative Pain, sponsored by Washington University School of Medicine.

Completed
Registry status
Phase 4
Development phase
123
Enrollment target
1
Study location

NCT02926573 is a Phase 4 study of Head and Neck Cancer and Postoperative Pain that has completed, run by Washington University School of Medicine. The registered enrollment target is 123 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02926573, a Phase 4 study of Head and Neck Cancer and Postoperative Pain, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
Phase 4
Development phase
123 participants
Enrollment target
1
Study location

Study Summary

Patient satisfaction with healthcare is increasingly being utilized as a metric to reflect provider and hospital quality of care. Furthermore, at the core of a healthcare team and healthcare system is the desire to provide patients with the best possible care in order to achieve the best possible outcomes. Providers have the duty to identify areas of needed improvement within the domains of treatment. An area of need that is ubiquitous within medicine is pain control; in this case acute postoperative pain control is the targeted condition. Studies have already shown that better control of acute postoperative pain leads to shortened hospital stays, reduced hospital costs and patient morbidity, improved patient satisfaction and a reduced likelihood of developing chronic pain. Research within the field of pain management has definitively revealed that a combination of different medication regimens can control acute postoperative pain better than narcotics alone. In particular, the medication gabapentin has been shown to improve acute postop pain in many kinds of surgical settings, and it is a safe medication with arguably fewer side effects than narcotics. The investigators know that certain groups of post surgical otolaryngology patients can be at risk for high levels of postoperative pain. Given all of this information, physicians have a responsibility to utilize medications such as gabapentin to do a better job of controlling patient's pain. This investigation is a quality improvement project designed to elucidate the benefits of gabapentin in pain management in patients undergoing surgery of the head and neck mucosal surfaces. It will provide much needed data in an understudied population and ultimately will improve the practice of pain management, patient satisfaction and quality of care delivered in the Barnes otolaryngology department.

Interventions

  • DRUG Placebo
  • DRUG Gabapentin

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2016-06-24
Est. Completion 2017-06-21
Phase Phase 4

What the Registry Record Tells You About NCT02926573

The ClinicalTrials.gov registry entry for NCT02926573 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (53% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02926573 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT02926573 about?

NCT02926573 is a clinical study titled "Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients". Patient satisfaction with healthcare is increasingly being utilized as a metric to reflect provider and hospital quality of care. Furthermore, at the core of a healthcare team and healthcare system is the desire to provide patients with the best possible care in order to achieve the best possible ou...

What is the current status of trial NCT02926573?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 123 participants. The study started on 2016-06-24. Estimated completion is 2017-06-21.

What conditions does trial NCT02926573 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Postoperative Pain, Acute Pain.

What interventions are being tested in trial NCT02926573?

The interventions under investigation include: Placebo (DRUG), Gabapentin (DRUG).

Who is sponsoring clinical trial NCT02926573?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02926573 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.